Codiak Biosciences

Codiak BioSciences, a clinical-stage biopharmaceutical company, was established to pioneer exosome-based therapeutics. The company was founded in 2015, emerging from the work of Raghu Kalluri, M.D., Ph.D., at the University of Texas MD Anderson Cancer Center. It was launched with significant initial funding from ARCH Venture Partners and Flagship Pioneering, among others. The scientific foundation of the company rests on the discovery that exosomes, which are natural nano-sized vesicles used by cells for communication, can be engineered to carry therapeutic payloads.

The company's core technology is its proprietary engEx™ Platform, which designs and engineers exosomes to deliver a variety of therapeutic molecules—such as drugs and genetic material—to specific cells and tissues. This platform aims to overcome challenges faced by other drug delivery methods by utilizing the natural ability of exosomes to travel throughout the body and be taken up by target cells. Codiak's business model focused on developing a pipeline of therapeutic candidates to treat a wide array of diseases, including cancer, neurological disorders, and infectious diseases. Revenue generation was anticipated through the successful development and commercialization of these drug candidates, potentially via partnerships or direct sales.

Codiak's journey included a notable initial public offering (IPO) in 2020. However, the company faced significant financial challenges. In a turn of events, Codiak BioSciences filed for Chapter 11 bankruptcy protection in March 2023. Following the bankruptcy filing, the company's assets were acquired, leading to the cessation of its original operations and delisting from the stock market.

Keywords: exosome therapeutics, biopharmaceutical, oncology, drug delivery, clinical-stage, engEx Platform, neuro-oncology, neurology, Chapter 11, asset acquisition